PL362477A1 - Inhibitory reduktazy HMG-CoA i sposób leczenia - Google Patents

Inhibitory reduktazy HMG-CoA i sposób leczenia

Info

Publication number: PL362477A1
Authority: PL; Poland
Prior art keywords: hmg; medicaments; treatment; related diseases; coa reductase
Prior art date: 2000-06-15

Application number

PL01362477A

Other languages

English (en)

Inventor

Jeffrey A. Robl

Bang-Chi Chen

Chong-Qing Sun

Original Assignee

Bristol-Myers Squibb Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-06-15

Filing date

2001-06-12

Publication date

2004-11-02

2001-06-12 Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company

2004-11-02 Publication of PL362477A1 publication Critical patent/PL362477A1/pl

Links

HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title 2
229940121710 HMGCoA reductase inhibitor Drugs 0.000 title 1
235000012000 cholesterol Nutrition 0.000 title 1
201000010099 disease Diseases 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
239000003814 drug Substances 0.000 title 1
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 title 1
229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/10—Aza-phenanthrenes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Obesity (AREA)
Orthopedic Medicine & Surgery (AREA)
Virology (AREA)
Endocrinology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Molecular Biology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Tropical Medicine & Parasitology (AREA)
Hospice & Palliative Care (AREA)
AIDS & HIV (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Child & Adolescent Psychology (AREA)
Gynecology & Obstetrics (AREA)
Reproductive Health (AREA)

PL01362477A 2000-06-15 2001-06-12 Inhibitory reduktazy HMG-CoA i sposób leczenia PL362477A1 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US21159400P	2000-06-15	2000-06-15
PCT/US2001/018868 WO2001096311A2 (en)	2000-06-15	2001-06-12	Hmg-coa reductase inhibitors and their use as medicaments for the treatment of cholesterol related diseases

Publications (1)

Publication Number	Publication Date
PL362477A1 true PL362477A1 (pl)	2004-11-02

Family

ID=22787566

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL01362477A PL362477A1 (pl)	2000-06-15	2001-06-12	Inhibitory reduktazy HMG-CoA i sposób leczenia

Country Status (20)

Country	Link
US (1)	US20020028826A1 (pl)
EP (1)	EP1294696A2 (pl)
JP (1)	JP2004503541A (pl)
KR (1)	KR20030010720A (pl)
CN (1)	CN1436174A (pl)
AR (1)	AR028732A1 (pl)
AU (1)	AU2001266860A1 (pl)
BR (1)	BR0111571A (pl)
CA (1)	CA2412979A1 (pl)
CZ (1)	CZ20023931A3 (pl)
EC (1)	ECSP024386A (pl)
HU (1)	HUP0302955A3 (pl)
IL (1)	IL152718A0 (pl)
MX (1)	MXPA02012415A (pl)
NO (1)	NO20026011L (pl)
PE (1)	PE20011364A1 (pl)
PL (1)	PL362477A1 (pl)
UY (1)	UY26776A1 (pl)
WO (1)	WO2001096311A2 (pl)
ZA (1)	ZA200210102B (pl)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20110196039A9 (en) *	1994-10-05	2011-08-11	Kaesemeyer Wayne H	Controlled release arginine formulations
CZ2003390A3 (en) *	2000-08-15	2004-03-17	Pfizer Products Inc.	Therapeutic combination of a cetp inhibitor and atorvastatin
CZ20033329A3 (cs) *	2001-06-06	2004-11-10	Bristol-Myers Squibb Company	Způsob přípravy chirálních sulfondiolů a dihydroxykyselin inhibitorů HMG CoA reduktázy
WO2003005999A2 (en)	2001-07-11	2003-01-23	Boehringer Ingelheim Pharmaceuticals, Inc.	Methods of treating cytokine mediated diseases
BR0212512A (pt)	2001-09-14	2004-10-26	Tularik Inc	Composto, composição farmacêutica e métodos para tratar um distúrbio, condição ou doença, elevar os nìveis do colesterol hdl, reduzir os nìveis de triglicerìdeo, tratar diabete, diminuir a resistência à insulina ou diminuir a pressão arterial e modular a ppardelta
GB0205166D0 (en)	2002-03-06	2002-04-17	Astrazeneca Ab	Chemical compounds
GB0205170D0 (en)	2002-03-06	2002-04-17	Astrazeneca Ab	Chemical compounds
GB0205175D0 (en)	2002-03-06	2002-04-17	Astrazeneca Ab	Chemical compounds
GB0205176D0 (en)	2002-03-06	2002-04-17	Astrazeneca Ab	Chemical compounds
GB0205165D0 (en)	2002-03-06	2002-04-17	Astrazeneca Ab	Chemical compounds
GB0205162D0 (en)	2002-03-06	2002-04-17	Astrazeneca Ab	Chemical compounds
US20040005358A1 (en) *	2002-04-23	2004-01-08	Slugg Peter H.	Modified-release vasopeptidase inhibitor formulation, combinations and method
US20050192245A1 (en) *	2002-07-18	2005-09-01	Sankyo Company, Limited	Medicinal composition for treating arteriosclerosis
CA2493384A1 (en) *	2002-07-18	2004-01-29	Sankyo Company Limited	Medicinal composition for treating arteriosclerosis
DE60313339T2 (de) *	2002-07-31	2008-01-03	Critical Outcome Technologies, Inc.	Protein tyrosin kinase inhibitoren
GB0220885D0 (en) *	2002-09-09	2002-10-16	Novartis Ag	Organic compounds
US7629347B2 (en) *	2002-10-09	2009-12-08	Critical Outcome Technologies, Inc.	Protein tyrosine kinase inhibitors
FR2848452B1 (fr) *	2002-12-12	2007-04-06	Aventis Pharma Sa	Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer
EA009646B1 (ru)	2003-05-30	2008-02-28	Рэнбакси Лабораториз Лтд.	Замещённые производные пиррола и их применение в качестве ингибиторов hmg-coa
ATE535614T1 (de)	2003-12-30	2011-12-15	Kowa Co	Screening-verfahren fuer gamma-sekretase- inhibitoren
EP1729761A4 (en) *	2004-03-05	2008-09-03	Eisai Co Ltd	TREATMENT OF CADASIL WITH CHOLINESTERASE INHIBITORS
CN1960781A (zh) *	2004-04-14	2007-05-09	沃尼尔·朗伯有限责任公司	治疗阿尔茨海默氏病的治疗组合
DE602005025755D1 (de)	2004-06-04	2011-02-17	Teva Pharma	Irbesartan enthaltende pharmazeutische zusammensetzung
EP1868653A2 (en) *	2005-04-12	2007-12-26	PSivida Inc.	Hmgcoa reductase inhibitor codrugs and uses thereof
WO2007016306A2 (en) *	2005-08-01	2007-02-08	Psivida Inc.	HMGCoA REDUCTASE INHIBITOR CODRUGS AND USES THEREOF
JP2009514851A (ja)	2005-11-08	2009-04-09	ランバクシーラボラトリーズリミテッド	（３ｒ，５ｒ）−７−［２−（４−フルオロフェニル）−５−イソプロピル−３−フェニル−４−［（４−ヒドロキシメチルフェニルアミノ）カルボニル］−ピロール−１−イル］−３，５−ジヒドロキシ−ヘプタン酸ヘミカルシウム塩の製法
EP1982710B1 (en) *	2006-02-07	2013-12-18	Mochida Pharmaceutical Co., Ltd.	Composition for prevention of recurrence of stroke
CN103217520A (zh) *	2006-02-27	2013-07-24	靶向分子诊断有限责任公司	用于减少细胞脂肪和预测用酪氨酸激酶抑制剂治疗后的心脏毒性的组合物和方法
EP2000137B1 (en) *	2006-03-29	2015-10-21	Kowa Company, Ltd.	Triglyceride-lowering agent and hyperinsulinism-ameliorating agent
WO2008059519A2 (en) *	2006-09-25	2008-05-22	Glenmark Pharmaceuticals Limited	A process for the preparation of intermediates of rosuvastatin
EP2121681B1 (en)	2007-01-11	2015-04-15	Critical Outcome Technologies, Inc.	Compounds and method for treatment of cancer
US8404275B2 (en) *	2007-07-01	2013-03-26	Vitalis Llc	Combination tablet with chewable outer layer
KR100900044B1 (ko) *	2007-07-05	2009-06-01	한국식품연구원	3-하이드록시-3-메틸글루타릴 보조효소 ａ 환원효소 저해용펩타이드 및 이를 함유하는 고콜레스테롤로 인한 심장질환 및 심혈관계 질환 치료제
TWI432195B (zh)	2007-10-03	2014-04-01	Kowa Co	神經細胞死亡抑制劑
CA2710039C (en) *	2007-12-26	2018-07-03	Critical Outcome Technologies, Inc.	Semicarbazones, thiosemicarbazones and related compounds and methods for treatment of cancer
EP2318406B1 (en)	2008-07-17	2016-01-27	Critical Outcome Technologies, Inc.	Thiosemicarbazone inhibitor compounds and cancer treatment methods
KR101104335B1 (ko) *	2009-03-06	2012-01-16	가톨릭대학교 산학협력단	알카노일화된 히알루론산으로 형성된 나노입자 및 그 제조방법
EP2552915B1 (en)	2010-04-01	2017-07-19	Critical Outcome Technologies Inc.	Compounds for the treatment of hiv
US9056134B2 (en) *	2010-07-21	2015-06-16	Nucitec S.A. De C.V.	Single daily dosage form for prevention and treatment of metabolic syndrome
US8877221B2 (en)	2010-10-27	2014-11-04	Warsaw Orthopedic, Inc.	Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same
US9107983B2 (en)	2010-10-27	2015-08-18	Warsaw Orthopedic, Inc.	Osteoconductive matrices comprising statins
US8865900B2 (en)	2011-01-18	2014-10-21	Dsm Sinochem Pharmaceuticals Netherlands B.V.	Methyltetrazole sulfides and sulfones
CN103313983B (zh)	2011-01-18	2016-06-29	中化帝斯曼制药有限公司荷兰公司	在碱存在下制备他汀类化合物的方法
MX2013008285A (es)	2011-01-18	2013-09-13	Dsm Sinochem Pharm Bv	Procedimiento para la preparacion de diolsulfonas.
US9308190B2 (en)	2011-06-06	2016-04-12	Warsaw Orthopedic, Inc.	Methods and compositions to enhance bone growth comprising a statin
CA2853804C (en)	2011-10-28	2021-06-01	Vitalis Llc	Anti-flush compositions
MX359424B (es)	2011-12-09	2018-09-12	Dsm Sinochem Pharm Nl Bv	Proceso para la preparación de un precursor de estatina.
HUE032936T2 (en)	2011-12-09	2017-11-28	Dsm Sinochem Pharm Nl Bv	A method for producing thioprecursors of statins
JP6041985B2 (ja) *	2012-06-08	2016-12-14	ミレファインケミカルカンパニーリミテッド	結晶型ｔ−ブチル２−［（４Ｒ，６Ｓ）−６−ホルミル−２，２−ジメチル−１，３−ジオキサン−４−イル］アセテート及びその製造方法
US8652527B1 (en)	2013-03-13	2014-02-18	Upsher-Smith Laboratories, Inc	Extended-release topiramate capsules
US9101545B2 (en)	2013-03-15	2015-08-11	Upsher-Smith Laboratories, Inc.	Extended-release topiramate capsules
CN112159403B (zh)	2020-09-30	2022-04-15	复旦大学	一种用于合成他汀类药物的关键中间体的制备方法
CN114394961A (zh) *	2021-12-24	2022-04-26	江苏阿尔法药业股份有限公司	用臭氧做氧化剂制备瑞舒伐他汀钙中间体的方法
CN114213350B (zh) *	2021-12-29	2024-03-19	江苏福瑞康泰药业有限公司	一种他汀类药物中间体的制备方法
CN114437052B (zh) *	2021-12-31	2024-03-29	江苏阿尔法集团福瑞药业(宿迁)有限公司	一种利用连续流微通道反应器合成他汀类药物中间体的方法
CN114601039A (zh) *	2022-03-16	2022-06-10	江苏省农业科学院	一种提高热应激下绵羊发情率和受胎率的方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5506219A (en) *	1988-08-29	1996-04-09	E. R. Squibb & Sons, Inc.	Pyridine anchors for HMG-CoA reductase inhibitors

2001
- 2001-06-06 US US09/875,218 patent/US20020028826A1/en not_active Abandoned
- 2001-06-12 JP JP2002510454A patent/JP2004503541A/ja active Pending
- 2001-06-12 WO PCT/US2001/018868 patent/WO2001096311A2/en not_active Ceased
- 2001-06-12 MX MXPA02012415A patent/MXPA02012415A/es unknown
- 2001-06-12 CN CN01811219A patent/CN1436174A/zh active Pending
- 2001-06-12 CA CA002412979A patent/CA2412979A1/en not_active Abandoned
- 2001-06-12 BR BR0111571-5A patent/BR0111571A/pt not_active IP Right Cessation
- 2001-06-12 HU HU0302955A patent/HUP0302955A3/hu unknown
- 2001-06-12 IL IL15271801A patent/IL152718A0/xx unknown
- 2001-06-12 AU AU2001266860A patent/AU2001266860A1/en not_active Abandoned
- 2001-06-12 PL PL01362477A patent/PL362477A1/pl not_active Application Discontinuation
- 2001-06-12 EP EP01944449A patent/EP1294696A2/en not_active Withdrawn
- 2001-06-12 KR KR1020027017087A patent/KR20030010720A/ko not_active Withdrawn
- 2001-06-12 CZ CZ20023931A patent/CZ20023931A3/cs unknown
- 2001-06-15 PE PE2001000579A patent/PE20011364A1/es not_active Application Discontinuation
- 2001-06-15 AR ARP010102885A patent/AR028732A1/es not_active Application Discontinuation
- 2001-06-15 UY UY26776A patent/UY26776A1/es not_active Application Discontinuation
2002
- 2002-12-12 ZA ZA200210102A patent/ZA200210102B/en unknown
- 2002-12-12 EC EC2002004386A patent/ECSP024386A/es unknown
- 2002-12-13 NO NO20026011A patent/NO20026011L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
WO2001096311A2 (en)	2001-12-20
CN1436174A (zh)	2003-08-13
UY26776A1 (es)	2002-01-31
HUP0302955A3 (en)	2005-08-29
JP2004503541A (ja)	2004-02-05
NO20026011L (no)	2003-02-12
CA2412979A1 (en)	2001-12-20
IL152718A0 (en)	2003-06-24
WO2001096311A3 (en)	2002-07-11
CZ20023931A3 (cs)	2003-03-12
ECSP024386A (es)	2003-03-10
HUP0302955A2 (hu)	2003-12-29
AU2001266860A1 (en)	2001-12-24
MXPA02012415A (es)	2003-06-06
US20020028826A1 (en)	2002-03-07
BR0111571A (pt)	2003-07-01
NO20026011D0 (no)	2002-12-13
EP1294696A2 (en)	2003-03-26
KR20030010720A (ko)	2003-02-05
PE20011364A1 (es)	2002-02-27
AR028732A1 (es)	2003-05-21
ZA200210102B (en)	2004-03-12

Legal Events

Date	Code	Title	Description
2009-03-31	REFS	Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)

Publication	Publication Date	Title
PL362477A1 (pl)	2004-11-02	Inhibitory reduktazy HMG-CoA i sposób leczenia
AU2002251841A1 (en)	2002-08-12	Compositions and methods for the therapy and diagnosis of pancreatic cancer
AU2002241520A1 (en)	2003-03-03	Blood assessment of injury
AU2004208615B2 (en)	2007-05-03	Medicine for prevention of and treatment for arteriosclerosis and hypertension
AU2003256253A1 (en)	2003-12-02	Aerosol for medical treatment and methods
SI1487541T1 (sl)	2009-02-28	Uporaba inhibitorjev il-18 za zdravljenje in /alipreventivo bolezni perifernega oĺ˝ilja
AU2003216592A8 (en)	2003-10-20	Pyrimidone derivatives useful for the treatment of inflammatin and immunological diseases
AU2002248319A1 (en)	2002-08-12	Pharmaceutical composition for the prevention and treatment of scar tissue
HUP0401605A3 (en)	2012-09-28	Integrin inhibitors for the treatment of eye diseases
AU2001269314A1 (en)	2002-01-21	Therapeutic and prophylactic use of reduced forms of pharmaceutical compounds
AU2002237667A1 (en)	2002-05-27	Methods for the treatment and prevention of urinary stone disease
AU2001249262A1 (en)	2001-10-03	Therapeutic compounds for the treatment of asthma and allergy, and methods of use thereof
AU2002339439A1 (en)	2003-02-24	Use of heparin-binding domain of fibronectin for diagnosis and treatment of cancer
AU3270301A (en)	2001-05-30	Combined pde3 and pde4 inhibitor therapy for the treatment of obesity
HUP0303306A3 (en)	2005-12-28	Use of il-18 inhibitors for the treatment and/or prevention of heart disease
AU2003262229A1 (en)	2004-03-11	Preventive and/or therapeutic drugs for asthma
AU2432001A (en)	2001-06-25	Treatment of mental conditions including depression
AU2003291368A1 (en)	2004-06-03	Compounds for the treatment of tobacco dependence and withdrawal
AU5680900A (en)	2001-01-31	Combination of mtp inhibitors and hmg-coa reductase inhibitors and the use thereof in medicaments
AU2001271284A1 (en)	2001-12-17	Compositions and methods for the therapy and diagnosis of pancreatic cancer
AU2003213898A1 (en)	2003-10-13	Prevention and treatment of mycoplasma-associated diseases
AU2001296224A1 (en)	2002-02-18	Compositions and methods for the therapy and diagnosis of pancreatic cancer
HK1051682A (en)	2003-08-15	Hmg-coa reductase inhibitors and their use as medicaments for the treatment of cholesterol related diseases
AU2001267165A1 (en)	2002-01-14	Prevention and treatment of mycoplasma-associated diseases
AU2002351798A1 (en)	2003-05-12	Methods and dosage forms for improving the bioavailability of therapeutic agents